Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Cervical Cancer
Interventions: intracavitary balloon brachytherapy, external beam radiation therapy, intensity-modulated radiation therapy, radiation therapy treatment planning/simulation, 3-dimensional conformal radiation therapy, Cisplatin; Radiation · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HEAD & NECK Cancer
Interventions: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cervical Cancer
Interventions: cetuximab, cisplatin; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 18
States / cities: Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more

Conditions: Head and Neck Cancer, Taste Dysfunction
Interventions: Miraculin, Miracle Fruit Placebo Cube; Drug · Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: FID007; Drug
Lead sponsor: Fulgent Pharma LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 3 more

Conditions: Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy
Interventions: Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, Esophageal Cancer
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions: INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more

Conditions: Lung Cancer, Head and Neck Cancer
Interventions: Panobinostat (LBH589), erlotinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Oral Complications of Radiation Therapy, Stage I Laryngeal Cancer, Stage II Laryngeal Cancer
Interventions: laser therapy, questionnaire administration; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Depression
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Gastric Cancer, Esophageal Neoplasms
Interventions: T900607-sodium intravenous; Drug
Lead sponsor: Tularik; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 5
States / cities: Los Gatos, California • San Diego, California • Tampa, Florida + 2 more

Conditions: Thyroid Cancer
Interventions: ZD6474 (vandetanib); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Little Rock, Arkansas • Boston, Massachusetts

Conditions: Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
Interventions: Combination of Varlilumab and Atezolizumab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Pain, Acute, Vocal Fold Polyp, Vocal Cord Paralysis, Laryngeal Neoplasms
Interventions: Vibroacoustic stimulation on, Augmented Reality on, Vibroacoustic stimulation off, Augmented reality off; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Head and Neck Neoplasms
Interventions: Registry; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer
Interventions: ponatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Xevinapant, IMRT, Placebo; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more

Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Tongue Cancer
Interventions: cetuximab, cisplatin, external beam radiation therapy, laboratory biomarker analysis; Biological · Drug · Radiation + 1 more
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Fatigue, Lung Cancer, Lymphoma, Ovarian Cancer, Prostate Cancer
Interventions: exercise intervention, complementary or alternative medicine procedure, fatigue assessment and management, physical therapy; Behavioral · Procedure
Lead sponsor: University of Utah; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

High-dose ICE With Amifostine

A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures

Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors